Citizens JMP initiated coverage of Kalaris Therapeutics (KLRS) with an Outperform rating and $20 price target The company is developing a next-generation, anti-VEGF candidate, TH103, that could translate to a best-in-class profile for the multi-billion dollar wet age-related macular degeneration, diabetic macular eedem, diabetic retinopathy, and retinal vein occlusion markets, the analyst tells investors in a research note. The firm says anti-VEGFs have built an over $15B market with room for improvement.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KLRS: